Epidemiological characteristics and antimicrobial susceptibility among carbapenem-resistant non-fermenting bacteria in Brazil

Journal of Infection in Developing Countries

Volumn 10, Issue 6, 2016, Pages 544-553

  Dias, Vanessa Cordeiro ^a,b   Diniz, Cláudio Galuppo ^a   Peter, Ana Cláudia De Oliveira ^b   Bastos, André Netto ^b   Bastos, Victor Quinnet De Andrade ^b   Bastos, Lucas Quinnet De Andrade ^b   da Silva, Vânia Lúcia ^a  

^a FEDERAL UNIVERSITY OF JUIZ DE FORA   (Brazil)

^b Cortes Villela Clinical Laboratory ^*  (Brazil)

Author keywords

Acinetobacter; Carbapenem resistant bacteria; Pseudomonas

Indexed keywords

AMIKACIN; AZTREONAM; CARBAPENEM; CEFEPIME; CEFTAZIDIME; CIPROFLOXACIN; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; POLYMYXIN B; SULTAMICILLIN; TETRACYCLINE; ANTIINFECTIVE AGENT; BETA LACTAMASE; CARBAPENEM DERIVATIVE;

ACINETOBACTER; ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATION; BLAOXA 143 GENE; BLAOXA 23 GENE; BLAOXA 24 GENE; BLAOXA 51 GENE; BLAOXA 58 GENE; BRAZIL; CARBAPENEM RESISTANT NON FERMENTING BACTERI; CROSS-SECTIONAL STUDY; DISK DIFFUSION; ESCHERICHIA COLI; FEMALE; GENE; GENERAL ASPECTS OF DISEASE; GENOTYPE; HUMAN; INHIBITION ZONE; MAJOR CLINICAL STUDY; MALE; MORTALITY RATE; NONHUMAN; OXACILLINASE GENE; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; STAPHYLOCOCCUS AUREUS; ACINETOBACTER BAUMANNII; ADOLESCENT; CHILD; DRUG EFFECTS; GENETICS; GRAM-NEGATIVE BACTERIAL INFECTIONS; INFANT; ISOLATION AND PURIFICATION; MICROBIOLOGY; MIDDLE AGED; MORTALITY; MULTIDRUG RESISTANCE; NEWBORN; PRESCHOOL CHILD; SURVIVAL ANALYSIS; VERY ELDERLY; YOUNG ADULT;

ACINETOBACTER BAUMANNII; ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; BRAZIL; CARBAPENEMS; CHILD; CHILD, PRESCHOOL; CROSS-SECTIONAL STUDIES; DISK DIFFUSION ANTIMICROBIAL TESTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; GRAM-NEGATIVE BACTERIAL INFECTIONS; HUMANS; INFANT; INFANT, NEWBORN; MALE; MIDDLE AGED; POLYMERASE CHAIN REACTION; PSEUDOMONAS AERUGINOSA; SURVIVAL ANALYSIS; YOUNG ADULT;

EID: 84976541685     PISSN: 20366590     EISSN: 19722680     Source Type: Journal    
DOI: 10.3855/jidc.6640     Document Type: Article

References (50)

1. Mesaros N, Nordmann P, Plésiat P, Roussel-Delvallez MR, Van Eldere J, Glupczynski Y, Van Laethem Y, Jacobs F, Lebecque P, Malfroot A, Tulkens PM, Van Bambeke F (2007) Pseudomonas aeruginosa: resistance and therapeutic options at the turn of the millennium. Clin Microbiol Infect 13: 560-578.
2. Perez F, Hujer AM, Hujer KM, Decker BK, Rather PN, Bonomo RA (2007) Global challenge of multi-drug resistant Acinetobacter baumannii. Antimicrob Agents Chemother 51: 3471-3484.
3. Paterson DL (2006) The epidemiological profile of infections with multidrug-resistant Pseudomonas aeruginosa and Acinetobacter species. Clin Infect Dis 43 Suppl 2: 43-48.
4. Furtado GH, Martins ST, Machado AM, Wey SB, Medeiros SA (2006) Clinical culture surveillance of carbapenemresistant Pseudomonas aeruginosa and Acinetobacter species in a teaching hospital in São Paulo, Brazil: a 7‐year study. Infect Control Hosp Epidemiol 27: 1270-1273.
5. Rice LB (2006) Challenges in identifying new antimicrobial agents effective for treating infections with Acinetobacter baumannii and Pseudomonas aeruginosa. Clin Infect Dis 43 Suppl 2: 100-105.
6. Scheffer MC, Bazzo ML, Steindel M, Darini AL, Clímaco E, Dalla-Costa LM (2010) Intra-hospital spread of carbapenemresistant Pseudomonas aeruginosa in a University Hospital in Florianópolis, Santa Catarina, Brazil. Rev Soc Bras Med Trop 43: 367-371.
7. Adams-Haduch JM, Paterson DL, Sidjabat HE, Pasculle AW, Potoski BA, Muto CA, Harrison LH, Doi Y (2008) Genetic basis of multidrug resistance in Acinetobacter baumannii clinical isolates at a tertiary medical center in Pennsylvania. Antimicrob Agents Chemother 52: 3837-3843.
8. Amudhan MS, Sekar U, Kamalanathan A, Balaraman S (2012) blaIMP and blaVIM mediated carbapenem resistance in Pseudomonas aeruginosa and Acinetobacter species in India. J Infect Dev Ctries 6: 757-762. doi:10.3855/jidc.2268.
9. Bonomo RA, Szabo D (2006) Mechanism of multidrug-resistant Acinetobacter species and Pseudomonas aeruginosa. Clin Infect Dis 43 Suppl 2: 49-56.
10. Rasmussen JW, Hoiby N (2006) OXA-types carbapenemases. J Antimicrob Chemother 57: 373-383.
11. Nordmann P, Poirel L (2002) Emerging carbapenemases in Gram negative aerobes. Clin Microbiol Infect 8: 321-331.
12. Lu PL, Doumith M, Livermore DM, Chen TP, Woodford N (2009) Diversity of carbapenem resistance mechanisms in Acinetobacter baumannii from a Taiwan hospital: spread of plasmid-borne OXA-72 carbapenemase. J Antimicrob Chemother 63: 641-647.
13. Morovat T, Bahram F, Mohammad E, Setareh S, Mehdi FM (2009) Distribution of different carbapenem resistant clones of Acinetobacter baumannii in Tehran Hospitals. New Microbiol 32: 265-271.
14. Perez F, Endimiani A, Ray AJ, Decker BK, Wallace CJ, Hujer KM, Ecker DJ, Adams MD, Toltzis P, Dul MJ, Windau A, Bajaksouzian S, Jacobs MR, Salata RA, Bonomo RA (2010) Carbapenem-resistant Acinetobacter baumannii and Klebsiella pneumoniae across a hospital system: impact of post acute care facilities on dissemination. J Antimicrob Chemother 65: 1807-1818.
15. Nowak P, Paluchowska P, Budak A (2012) Distribution of blaOXA genes among carbapenem resistant Acinetobacter baumannii nosocomial strains in Poland. New Microbiol 35: 317-325.
16. Poirel L, Nordmann P (2006) Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology. Clin Microbiol Infect 12: 826-836.
17. Turton JF, Woodford N, Glover J, Yarde S, Kaufmann ME, Pitt TL (2005) Identification of Acinetobacter baumannii by detection of blaOXA-51-like carbapenemase gene intrinsic to this species. J Clin Microbiol 44: 2974-2976.
18. Poirel L, Marqué S, Héritier C, Segonds C, Chabanon G, Nordmann P (2005) OXA-58, a novel class D {beta}-lactamase involved in resistance to carbapenems in Acinetobacter baumannii. Antimicrob Agents Chemother 49: 202-208.
19. Peleg AY, Franklin C, Walters LJ, Bell JM, Spelman DW (2006) OXA-58 and IMP-4 Carbapenem-Hydrolyzing β-lactamases in an Acinetobacter junii blood culture isolate from Australia. Antimicrob Agents Chemother 50: 399-400.
20. Coelho J, Woodford N, Afzal-Shah M, Livermore D (2006) Occurrence of OXA-58-like carbapenemases in Acinetobacter spp. collected over 10 years in three continents. Antimicrob Agents Chemother 50: 756-758.
21. Merkier AK, Catalano M, Ramírez MS, Quiroga C, Orman B, Ratier L, Famiglietti A, Vay C, Di Martino A, Kaufman S, Centrón D (2008) Polyclonal spread of bla(OXA-23) and bla(OXA-58) in Acinetobacter baumannii isolates from Argentina. J Infect Dev Ctries 2: 235-240. doi:10.3855/jidc.269.
22. Liakopoulos A, Miriagou V, Katsifas EA, Karagouni AD, Daikos GL, Tzouvelekis LS, Petinaki E (2012) Identification of OXA-23 producing Acinetobacter baumannii in Greece, 2010-2011. Euro Surveill 17: 5.
23. Zhang JP, Zhu W, Tian SF, Chu YZ, Chen BY (2010) Molecular characteristics and resistant mechanisms of imipenem-resistant Acinetobacter baumannii isolates in Shenyang, China. J Microbiol 48: 689-694.
24. Carretto E, Barbarini D, Dijkshoorn L, van der Reijden TJ, Brisse S, Passet V, Farina C; APSI Acinetobacter Study Group (2011) Widespread carbapenem resistant Acinetobacter baumannii clones in Italian hospitals revealed by a multicenter study. Infect Genet Evol 11: 1319-1326.
25. Poirel L, Naas T, Nordmann P (2010) Diversity, epidemiology and genetics of class D beta-lactamases. Antimicrob Agents Chemother 54: 24-38.
26. Higgins PG, Poirel L, Lehmann M, Nordman P, Seifert H (2009) OXA-143, a novel carbapenem-hydrolysing class D β-lactamase in Acinetobacter baumannii. Antimicrob Agents Chemother 53: 5035-5038.
27. Medeiros M, Lincopan N (2013) Oxacillinase (OXA) producing Acinetobacter baumannii in Brazil: clinical and enviromental impact and therapeutic options. Braz J Pathol Lab Med 49: 391-405.
28. Towner KJ, Evans B, Villa B, Levi K, Hamouda A, Amyes SG, Carattoli A (2011) Distribution of intrinsic plasmid replicase genes and their association with carbapenem hydrolyzing class D β-lactamase genes in European clinical isolates of Acinetobacter baumannii. Antimcrob Agents Chemother 55: 2154-2159.
29. Mostachio AK, Levin AS, Rizek C, Rossi F, Zerbini J, Costa SF (2012) High prevalence of OXA-143 and alteration of outer membrane proteins in carbapenem-resistant Acinetobacter spp. isolates in Brazil. Int J Antimicrob Agents 39: 396-401.
30. ANVISA – National Health Surveillance Agency (2004) Clinical Microbiology Manual for Infection Control in Health Services. 1st ed. Available: http://www.anvisa.gov.br/servicosaude/microbiologia/introducao.pdf. Accessed on June 27, 2015.
31. Clinical and Laboratory Standards Institute (2012) Performance standards for antimicrobial susceptibility testing: 22th information supplement. M100-S22. Wayne, PA: CLSI.
32. Jones RN, Ferraro MJ, Reller B, Schreckenberger PC, Swenson JM, Sader HS (2007) Multicenter studies of tigecycline disk diffusion susceptibility results for Acinetobacter spp. J Clin Microbiol 45: 227-230.
33. Woodford N, Ellington MJ, Coelho JM, Turton JF, Ward M, Brown S, Amyes S, Livermore DM (2006) Multiplex PCR for genes enconding prevalent OXA carbapenemases in Acinetobacter spp. Int J Antimicrob Agents 27: 351-353.
34. Hammami S, Boutiba-Ben Boubaker I, Ghozzi R, Saidani M, Amine S, Ben-Redjeb S (2011) Nosocomial outbreak of imipenem-resistant Pseudomonas aeruginosa producing VIM-2 metallo-β-lactamase in a kidney transplantation unit. Diag Pathol 6: 106.
35. Peña C, Suarez C, Tubau F, Dominguez A, Sora M, Pujol M, Gudiol F, Ariza J (2009) Carbapenem-resistant Pseudomonas aeruginosa: factors influencing multidrug-resistant acquisition in non-critically ill patients. Eur J Clin Microbiol Infect Dis 28: 519-522.
36. Mendes C, Oplustil C, Sakagami E, Turner P, Kiffer C; MYSTIC Brazil Group (2005) Antimicrobial susceptibility in intensive care units: MYSTIC Program Brazil 2002. Braz J Infect Dis 9: 44-51.
37. John S, Balagurunathan R (2011) Metalo-β-lactamase producing Pseudomonas aeruginosa and Acinetobacter baumannii. Indian J Med Microbiol 29: 302-304.
38. Correa LL, Botelho LA, Barbosa LC, Mattos CS, Carballido JM, Castro CL, Mondino PJ, de Paula GR, de Mondino SS, de Mendonça-Souza CR (2012) Detection of blaOXA-23 in Acinetobacter spp. isolated from patients of a university hospital. Braz J Infect Dis 16: 521-526.
39. Robledo IE, Aquino EE, Santé ML, Santana JL, Otero DM, León CF, Vazquez GJ (2010) Detection of KPC in Acinetobacter spp. in Puerto Rico. Antimicrob Agents Chemother 54: 1354-1357.
40. Gales AC, Jones RN, Sader HS (2006) Global assessment of the antimicrobial activity of polymyxin B against 54.731 clinical isolates of Gram negative bacilli: report from the SENTRY Antimicrobial Surveillance Program (2001-2004). Clin Microbiol Infect 12: 315-321.
41. Kempf M, Rolain JM (2012) Emergence of resistance to carbapenems in Acinetobacter baumannii in Europe: clinical impact and therapeutic options. Int J Antimicrob Agents 39: 105-114.
42. Carvalho KR, Carvalho-Assef AP, Peirano G, Santos LC, Pereira MJ, Asensi MD (2009) Dissemination of multidrug-resistant Acinetobacter baumannii genotypes carrying blaOXA-23 collected from hospitals in Rio de Janeiro, Brazil. Int J Antimicrob Agents 34: 25-28.
43. Martins AF, Kuchenbecker R, Sukiennik T, Boff R, Reiter KC, Lutz L, Machado AB, Barth AL (2009) Carbapenem-resistant Acinetobacter baumannii producing the OXA-23 enzyme: dissemination in southern Brazil. Infection 37: 474-476.
44. Martins AF, Kuchenbecker RS, Pilger KO, Pagano M, Barth AL; CMCIES-PMPA/SMS Task Force (2012) High endemic levels of multidrug-resistant Acinetobacter baumannii among hospitals in southern Brazil. Am J Infect Control 40: 108-112.
45. Furtado GH, Cavalcante AC, Medeiros EA, Gales AC, Oliveira VG, Girardo R (2011) Bloodstream infections with OXA-23 producing Acinetobacter baumannii isolates in a university affliliated hospital in Brazil: epidemiology and clinical outcomes. Am J Infect Control 39: 706-708.
46. Werneck JS, Picão RC, Girardello R, Cayô R, Margutti V, Dalla-Costa L, Gales AC, Antonio CS, Neves PR, Medeiros M, Mamizuka EM, Elmor de Araújo MR, Lincopan N (2011) Low prevalence of blaOXA-143 in private hospitals in Brazil. Antimicrob Agents Chemother 55: 4494-4495.
47. Antonio CS, Neves PR, Medeiros M, Mamizuka EM, Elmor de Araújo MR, Lincopan N (2011) High prevalence of carbapenem-resistant Acinetobacter baumannii carrying the blaOXA-143 gene in Brazilian hospitals. Antimicrob Agents Chemother 55: 1322-1323.
48. Rodriguez-Martínez JM, Poirel L, Nordman P (2009) Molecular Epidemiology and mechanism of carbapenem resistance in Pseudomonas aeruginosa. Antimicrob Agents Chemother 53: 4783-4788.
49. Tomás M, Doumith M, Warner M, Turton JF, Beceiro A, Bou G, Livermore DM, Woodford N (2010) Efflux pumps, OprD Porin, AmpC β-Lactamase and multiresistance in Pseudomonas aeruginosa isolates from cystic fibrosis patients. Antimicrob Agents Chemother 54: 2219-2224.
50. Xavier DE, Picão RC, Girardello R, Fehlberg LC, Gales AC (2010) Efflux pumps expression and its association with porin down regulation and β-lactamase production among Pseudomonas aeruginosa causing bloodstream infections in Brazil. BMC Microbiol 10: 217.